Scott Marshall, Ph.D., Co-Founder and CEO of QuartzBio has seen, first-hand, the need for better infrastructure to support the sample journey. It’s not something that can be fixed with more fragmented tools or manual workarounds.
Scott has spent years of working closely with clinical, sample, and biomarker operations teams, and he’s seen how quickly data, systems, and processes become disconnected as trials scale, creating inefficiencies, added risk, and delays.
The teams had tools, but those tools weren’t connected by a single, trusted foundation.
That realization ultimately led Scott and his co-founders to create QuartzBio, a SaaS platform designed to unify biospecimen, assay, and clinical data across the entire lifecycle.
We sat down with Scott to unpack the challenges he experienced, the factors that shaped the way he and his team built QuartzBio, and how the platform is now changing the way R&D teams manage and get value from sample operations in clinical trials.
